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Purpose: The role of physicians in the overall management of hypertension and their adherence to the 
JNC VII, WHO/ISH and ESH guidelines were examined in this study.  
Method: Case notes of hypertensive patients diagnosed between 1 January 2004 and 30
 
September 
2005, in the Cardiology Clinic of University of Benin Teaching Hospital were retrieved for evaluation. 
They were assessed for adherence to the JNC VII, WHO/ISH and ESH guidelines, in the management 
of hypertension. 
Result: Five hundred and one case notes were used in the study. Prevalence of hypertension was 
highest in the Grade 2 category (36%). More women (60%) than men (40%) were affected, with a 
diagnostic mean systolic blood pressure (SBP); male (164.0mmHg ± 21.9), female (163.7 mmHg ± 18.8) 
and mean diastolic blood pressure (DBP); male (100.1 mmHg ± 13.2), female (97.3 mmHg ± 13.1). After 
commencing treatment, mean SBP and DBP for male and female were (131.8 mmHg ± 11.6; 84.3 
mmHg ± 7.5), and (132.3 mmHg ± 11.5   83.2 mmHg ± 7.6), respectively. The commonest co-morbidity 
was diabetes mellitus (18%). Co-morbidity was commonest in Grade 2 (34%) and Grade 3 hypertension 
(34%). Almost half of the subjects (49%) were on a two-drug combination while 14% were on 
monotherapy. Calcium channel blockers were the most commonly prescribed anti-hypertensive drug 
(31%) followed by diuretics (30%). In combination drug regimen, diuretics were the commonest (74%). 
There was no evidence of body weight management in hypertension. 
Conclusion: Physicians in this hospital fairly complied with the stated guidelines, but do not appear to 
have recommended lifestyle modifications to their hypertensive patients.  
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INTRODUCTION 
Hypertension is considered a public health 
problem in sub-Saharan Africa, as it is 
increasing in importance as a major cause of 
cardiovascular disability and mortality. 
1
 The 
world over, treatment of hypertension has 
been demonstrated to be beneficial to the 
patients, yet the levels of control of blood 
pressure (BP) in sub-Saharan Africa is low. A 
Nigeria report, indicates that only 25.4% of 
patients attending a hypertensive clinic in a 




The need to improve the global control of high 
BP has necessitated the stipulation of various 
hypertension classification and treatment 
guidelines. In recent times, it includes those of 
World Health Organization/International 
Society of hypertension (WHO/ISH) 
2 
The 
Sixth and Seventh reports of the Joint 
National Committee on the Prevention, 
Detection, Evaluation and Treatment of 
Hypertension (JNC VI and JNC VII.)
3,4 
guidelines. 
Practice guidelines serve as useful tools for 
clinical decision making. They also help to 
reduce the variation in practice, guide 
appropriateness and measure quality of care.  
Many factors thought to be responsible for 
poor BP control in Africans have been 
evaluated, but the extent of adherence to 
treatment guidelines by key health care 
players such as doctors in the management of 
hypertension
5 
is yet to be ascertained in this 
environment. In places were similar studies 
have been done, reports showed divergent 
views on the influence of the guidelines on 
prescription patterns of doctors.
 6
 
This study aims to assess the extent of 
adherence of physicians in this environment to 
recently updated international guidelines in 
the management of hypertension. 
 
METHODS 
This retrospective study was carried out at 
University of Benin Teaching Hospital, Benin 
City, Nigeria. The first step was to retrieve the 
case notes of patients that attended the 
consultant out-patients’ clinics between 
September and November 2005, from the 
Medical Records Unit of the hospital.  
The case notes of patients who were first 
diagnosed to be hypertensive between 1 
January 2004 and 30 September 2005 were 
selected. Also selected were those previously 
diagnosed to be hypertensive, but defaulted 
from clinic attendance for at least one year 
were included only if they represented in the 
clinics during the period under consideration. 
This period (1 January 2004 to 30 September 
2005) was chosen because the JNC VII, 
European Society for Hypertension 
Guidelines
7 
and updated WHO/ISH 
Guidelines, 
8
 came into focus in 2003. 
 
All the case notes of patients who met the 
inclusion criteria and who were booked for 
their regular appointment during the study 
period were included. A total of 501 case 
notes of patients were selected and from them 
the following information were retrieved; age, 
gender, body weight, occupation, BP reading 
(systolic blood pressure; SBP and  diastolic 
blood pressure; DBP) at diagnosis and last 
clinic attendance, and the pattern of 
prescribed drugs for hypertension. In 
examining the prescribed drugs, attention was 
paid to whether the patient was on 
monotherapy or multitherapy. Multitherapy 
was defined as two or more drug 
combinations from different antihypertensive 
drug classes. Antihypertensive classes in the 
study included thiazide diuretics (D), beta-
blockers (BB), calcium channel blockers 
(CCB), angiotensin converting enzyme 
inhibitors (ACEIs), angiotensin receptor 
blockers (ARBs). The pattern of drug 
combination was also examined. The number 
of drug combinations in relation to increases 
in BP was noted. These were all reviewed 
against the recommendations of the treatment 
guidelines.  
According to JNC WHO/ISH and ESH 
guidelines, effective drug combinations 
include; (I) D and BB.  (II) D and ACEI/ARB. 
(III) CCB and BB. (IV) CCB and ACEI or ARB. 
(V) CCB and D. (VI) alpha–blocker and BB. 
(VII) Other combinations (e.g. with centrally 
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modulators, or ACEIs or ARBs) can be used, 
if necessary. (VIII) In many cases, 3 or 4 
drugs may be necessary. The BP profiles of 
the patients were also graded based on the 
above mentioned guidelines, i.e. pre-
hypertension, high normal, grade 1, 2, 3 
hypertension and isolated systolic 
hypertension. 
3,4
     
Subjects with co-morbidities were noted and 
the number of co-morbid conditions was 
reported as different disease entity. For 
example, the number of patients with diabetes 
mellitus, congestive heart failure et cetera was 
reported individually.     
 
Data collected were analysed using SPSS 
10.0 for Windows. The means of continuous 
variables (age, SBP, DBP, weight) were 
compared using Student t-test, with the level 
of significance set at P < 0.05. Categorical 
variables such as number of drug 
combinations in relation to increases in BP 
and the number of patients in the various BP 




Out of the 501 patients selected in line with 
set criteria, 60% of them were females, while 
40% were males.  
The mean diagnostic SBP for males was 
163.7 mmHg ± 18.8 and 164.0mmHg ± 21.9 
for females. The difference was not significant 
(P>0.05). However, the males had a 
significantly higher mean DBP (100.1 mmHg ± 
13.2) than females (97.3 mmHg ± 13.1) (P < 
0.05).There was a significant reduction in 
systolic and diastolic blood pressures in all 
subjects (P< 0.05) after commencement of 
treatment. However, this difference was not 
reflected between genders; the mean SBP 
and DBP after commencement of treatment in 
the males was (SBP; 131.8mmHg ± 11.6, 
DBP; 84.3mmHg ± 7.5) and females (SBP; 
132.3mmHg ± 11.5, DBP; 83.2mmHg ± 7.6). 
(Table 1)  
Based on the JNC VII classification a greater 
percentage of the patients (35.5%) belonged 
to the grade 2 hypertension category while the 
pre-hypertension class had the least (0.4%).  
When combined, patients in grade 2 and 3 
hypertension categories made up 67.5% of 
the study population. (Table 2). The 
prevalence of co-morbid condition increased 
with the severity of hypertension. It increased 
from 0.9% in pre-hypertension to 33.7% in 
grade 2 and grade 3 classes, respectively 
(Table 2). Diabetes mellitus (17.6%) was the 
commonest co-morbid condition followed by 
cardiovascular diseases (coronary heart 
disease, angina pectoris, myocardial 
infarction, 4.4% and congestive heart failure 
3.4%.  (Figure 1.) 
A combination of two anti-hypertensive 
medications was found to be most commonly 
used in the management of grades 1 and 2 
hypertension. Furthermore, it was also found 
that the number of drugs prescribed for 
patients increased with the severity of the 
disease 
As shown in Table 3, three-drug multitherapy 
was used in 12.0% of grade 1 hypertensive 
subjects, 31.5% of grade 2 and 40.0% of 
grade 3. In the same vein, 4 drugs were used 
in 2.8% of grade 2 cases and 23.1% of grade 
3 (Table 3). 
A wide variety of anti-hypertensive 
medications were used in this centre (Table 
4). The most commonly prescribed drug was 
CCB (31.3%), and this was followed by 
diuretics (29.7%). In those on monotherapy 
and two drug multitherapy, CCBs were the 
most commonly prescribed antihypertensives 
as it made up 40.6% and 36.2% of the drugs 
in the respective combinations (Table 4). But 
in drug combinations that had three or more 
drugs diuretics were the most frequently 
prescribed agents (3-drugs; 31.7%, 4-drugs; 
31.0%, 5-drugs; 40.0%). Calcium channel 
blockers plus diuretics was the commonest 2-
drug combination (36.6%), followed by CCB 
plus ACEI (19.5%) and CCB plus BB (11.4%). 
In the 3-drug combination, CCB plus diuretic 
plus BB was found in 32.9% of cases and this 
was closely followed by CCB plus diuretic plus 
ACEI (31.43%). The most frequent drug 
combination pattern in this centre was CCB 
plus diuretic (2-drugs group), CCB plus 
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diuretic plus BB (3-drugs group), and ACEI 
plus BB, plus CCB plus diuretic (4-drugs 
group). There was no prominent drug 
prescription pattern in the patients receiving a 
combination of 5 antihypertensive drugs. 
  
Table 1:  The profiles of patient’s age, weight, and systolic and diastolic blood pressure 
 
Variables    Male Mean (SD)  Female Mean (SD) P-value 
Age (Yr)     57.5 (12.8)  56.8 (13.6)  0.37 
Weight (Kg)    74.9 (14.0)  75.5 (16.4)  0.65  
Pre-treatment SBP (mmHg)  163.7 (18.8)  164.0 (21.9)  0.87   
Pre-treatment DBP (mmHg)  100.1 (13.2)  97.29 (13.1)  0.02 
Post-treatment SBP (mmHg)  131.8 (11.6)  132.3 (11.5)  0.67 
Post-treatment DBP (mmHg)  84.3 (7.5)  83.2 (7.6)  0.09 
 
 
Table 2: The number of subjects and co-morbid distribution in the different BP categories 
  
BP category  SBP/DBP        No. of Subjects   Male       Female     Co-Morbidity 
   (mmHg)                   (%)  n (%)          n (%)     n 
   
Pre- Hypertension 120-139/80-89  2 (0.40)  1 (50)  1 (50)    2 
High normal  130-139/85-99  3 (0.60)  1 (33.3)  2 (66.7)    3 
 
Grade 1  
 Hypertension  40-159/90-99  108 (21.6) 31 (28.7) 77 (71.3)  40 
 
Grade 2 
 Hypertension  60-179/100-109  178 (35.5) 81 (45.5) 97 (54.5)  68 
 
Grade 3  
Hypertension  ≥ 180/≥ 110  160 (31.9) 61 (38.1) 99 (61.9)  68 
Isolated Systolic   




Table 3:  Number of antihypertensive drugs prescribed with respect to the severity of hypertension 
   Hypertensive drug combination; number of subjects using the various  
BP category  No. of combinations. (%) 
(mmHg)     subjects   _________________________________________________________________ 
            1-drug             2-drug 3-drug    4-drug  5-drug 
_________________________________________________________________________________________ 
Pre- Hypertension 2 2 (100.0) -  -  -  - 
High normal  3 2 (66.7)  1 (33.7)  -   -  - 
Grade 1 
 Hypertension  108 38 (35.2) 57 (52.8) 13 (12.0) -  - 
Grade 2 
 Hypertension  178 14 (7.9)  103 (57.9) 56 (31.5) 5 (2.8)  - 
Grade 3  
Hypertension  160 8 (5.0)  47 (29.4) 64 (40.0) 37 (23.1) 4 
(2.5) 
Isolated Systolic   
Hypertension  50 5 (10.0)  38 (76.0) 7 (14.0)  -  - 
Total   501 69 (13.8) 246 (49.1) 140 (27.9) 42 (8.4)         4 (0.8) 
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Methyldopa is still being used as an 
antihypertensive in this environment. This was 
particularly observed in the higher drug 
combinations, where it was a component of 4-
drug combination to the extent of 33.3% and 
50.0% in the 5-drug combinations. Patients in 
these two classes of multitherapy only made 
up 9.2% of the study population. 
 
DISCUSSION 
It was observed that there were a higher 
number of women than men encountered over 
the study period, Some workers have opined 
that this is either because males do not 
regularly keep clinic appointments, 
9
 or it is a 
reflection of poorer awareness of BP status 
among them. In this study this fact seems 
reiterated by the observation of significantly 
higher mean pre-treatment DBP in men, 
despite a similar SBP in both sexes. Similar 
observation was noted elsewhere. 
(10, 11)
  
Most patients presented to the hospital with a 
mean BP consistent with the grade 2 
hypertension classification, this is similar to 
the finding of a study done in Ilorin, Nigeria.
12
 
In about 68% of the study population the pre-
treatment BP classifications were in grade 2 
and grade 3. This is disturbing especially with 
the observation that this group had the highest 
prevalence of co-morbidity. The authors were 
unable to ascertain how many of these 
subjects had a co-morbid condition at the time 
of their first visit. Treatment guidelines under 
focus emphasize the need to evaluate the 
total cardiovascular risk of patients before the 
commencement of drug treatment. It is 
advised therefore, that the evaluation of 
patients for possible co-morbidities should be 
emphasized in this environment giving their 
common late presentation. The subjects in the 
pre-hypertension and high normal groups, 
who were placed on drugs, were so treated 
probably because of the presence of co-
morbidities. This is in keeping with the 
treatment guidelines which states that the 
presence of co-morbidities in pre-hypertension 
and high normal BP necessitates the use of 
drugs. 
There was a ready recourse to the use of 
multitherapy in the subjects, as only 69 
(13.8%) of them were on monotherapy. A 
study in India 
13
 showed a common trend 
among patients attending a cardiology clinic, 
in which most of them were on multiple 
therapies with two combined 
antihypertensives. Like in the present study, 
this pattern is encouraged by the guidelines, 
which states that small doses of different 
classes of antihypertensive drug is more 
beneficial than a high dose of one. This advice 
probably accounts for 60% of antihypertensive 
drug visits in United States, getting 




The finding that CCB was most commonly 
prescribed drug in this study agrees with 
some other reports 
15 16
 which were done 
outside Nigeria. This was not the case in a 
study done in Ibadan, Nigeria
17
 where thiazide 
was the most commonly prescribed 
antihypertensive. The Ibadan study which was 
published in 2003 may probably be influenced 
by the volume dependency of black 
hypertensives and the ALLHAT study 
18
 
released in 2002. The ALLHAT study had 
emphasized the use of thiazide in its 
recommendations, and this has been reported 
to increase prescription pattern of the drug by 
physicians.
 19
 The difference in the level of 
thiazide use in this study and the Ibadan’s, 
could not be due to the factor of co-morbidity, 
because the prevalence of diabetics in the 
other study was 22% as against 17.5% in 
Ibadan. The present preference for CCB 
could, among other factors, be due to the 
influence of the treatment guideline. The 
Ibadan study mentioned that prescription of 
CCB, was already experiencing an upward 
trend at that time. It was noted in Ibadan, 
17
 
that monotherapy on CCB achieved 
normotension (<140/90mmHg) better than 
diuretics. This claim is cautioned by the work 
of Wassertheil-Smoller et al 
20
 which found 
that monotherapy with diuretic was equal or 
superior to others, in preventing CVD 
complications of high BP in women. 
Furthermore, it has been suggested that 
factors that should determine the use of 
thiazides are sex, age and co-morbidities. 
21
 
What this infers, is that in prescribing drugs for 
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hypertension, the role of gender should be 
taken into consideration. 
In the present study, CCB plus diuretic 
combination was the commonest multitherapy. 
The same combination has been reported to 
Table 4: The frequency of use of the different classes of antihypertensive medications and its 
occurrence in the various drug combinations for treatment of high BP 
 
 
Class of anti-  Nos of drugs Number of times a drug was prescribed in the different drug 
combination 
Hypertensive   prescribed for BP control (%) 
Drugs   (%) 
 ________________________________________________________________________________ 
     1-drug     2-drug           3-drug    4-drug  5-drug 
 
Diuretics (D)  347(29.7) 14(4.0)     140(40.4)     133(38.3)    52(15.0) 8(2.3) 
Beta-blockers (BB) 147(12.5) 3(2.0)      51(34.7)       62(42.2)    30(20.4) 1(0.7) 
Calcium Channel  
Blockers (CCB)  366(31.3) 28(7.7)      178(48.6)    119(32.5)   37(10.1) 4(1.1) 
ACEIs and ARBs  197(16.8) 21(10.7)      79(40.1)       64(32.5)  30(15.2) 3(1.5) 
Fixed drug 
combination (FDC) 33(2.8)  3(9.1)     14(42.4)       14(42.4) 2(6.1)  - 
*Miscellaneous  80(6.8)  -    31(38.8)        28(35.0) 17(21.3)  4(5.0) 
drugs 
Total   1170(100.0) 69(5.9)      493(42.1)   420(35.9) 168(14.4) 20(1.7)  
  
ACEIs = Angiotensin Converting Enzyme Inhibitors 
ARB = Angiotensin Recepor blocker 

















































































































































Fig 1: Frequency of occurrence of co-morbidities in hypertensive patients 
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have the best rate of BP control in one 
study.
16
 Similar to the earlier observation, this 
combination is said to be poor in women, as it 
has been associated with a higher risk of CVD 
mortality. 
20
 Other centres are in favour of the 
combination of CCB plus BB. 
15
 
We observed that, as the need for more 
classes of drug arose for BP control, the use 
of diuretic became more prominent. It was the 
commonest component of multitherapy in this 
study. This infers its usefulness in patients in 
this environment. According to the ESH 
guidelines, thiazides are useful in elderly 
patients, those with congestive heart failure, 
hypertensives of African origin. The higher 
prevalence of women in this study, mean age 
of the population and race, are factors that 
favour the use of diuretics in achieving BP 
control in the study population.  
A sore point in the study was the conspicuous 
absence of the use of non-pharmacological 
treatment option, such as body weight and 
lifestyle modifications. This has been 
documented to be associated with substantial 
savings in cost, 
22
 especially in an economy 
as obtainable in the country. There was no 
documentation of body mass index (BMI), 
except body weight in a few subjects. 
Previous reports have demonstrated a higher 





 hypertensives in Nigeria. Advice 
on lifestyle modifications was documented in 
only 1% of the subjects. These are 
inconsistent with the guidelines. 
 
CONCLUSION 
In conclusion, hypertensives are likely to 
present late in this community and when they 
do, they commonly require multitherapy for BP 
control. Physicians in this hospital complied 
fairly with the stated guidelines. However, they 
do not appear to recommend lifestyle 
modification to their patients in the 
management of hypertension.  
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